

Scientific Programme by Day and by Zone



How to use this section:

- Sessions are listed by Day, Time and Zone. Within each section each speaker and each author has a sequential number
 - On pages 529 to 642 there is an alphabetical index of authors and speakers with a sequential programme number
- Poster presenters are listed in the index and can be identified by the P before the sequential programme number
- **The index also contains all Chairpersons with the page number of the sessions they chair**

Together for better CVD prevention



A joint ESC and EACPR initiative to support the Highlight of this year's congress - Prevention of Cardiovascular Disease: from cell to man to society

Visit the Prevention Corner (Zone 4)

- **Get your free copy of the European Journal of Cardiovascular Prevention & Rehabilitation (EJCPR) Supplement**
- **Experience HeartScore®, the interactive tool for total CVD risk prediction & management**

Don't miss the **European Forum for Cardiovascular Disease Prevention in Clinical Practice - from guidelines to effective action** (Symposium).


Monday 31 August, 16:30 - 18:00, Room Tel Aviv (Zone 1)

For the first time in the official scientific programme of the ESC Congress, the 2009 edition will focus on how to

translate European Guidelines on CVD Prevention into effective action through practical take home messages on the remaining barriers to implementation, the political prerequisites for success, the factors influencing physician and patient behaviour and on how to put strategy into practice.

**Visit the ESC Stands for various CVD Prevention activities:
HeartScore® Live demos, Health Professional Toolkit...**

www.escardio.org/prevention



How to use this section:

- Sessions are listed by Day, Time and Zone
Within each section each speaker and each author has a sequential number
- On pages 529 to 642 there is an alphabetical index of authors and speakers with a sequential programme number
Poster presenters are listed in the index and can be identified by the P before the sequential programme number
- **The index also contains all Chairpersons with the page number of the sessions they chair**

No session

13:30 Coffee break

STUDY CONCEPTS AND ROUTES OF ADMINISTRATION IN AUTOLOGOUS STEM CELL THERAPY

Satellite

Chairperson(s): G. Steinhoff (Rostock, DE); F. Fernandez-Aviles (Madrid, ES)
Satellite Symposium organised by Miltenyi Biotec

- | | | |
|-------|---|---|
| 14:30 | Introduction: cellular therapy - Present aspects.
– F. Fernandez-Aviles (Madrid, ES) | 1 |
| 14:35 | Comparison of intracoronary and transendocardial injection of bone marrow-derived CD133⁺ cells in chronic ischemic patients.
– M.W. Bergmann (Hamburg, DE) | 2 |
| 14:50 | Intramyocardial transplantation of bone marrow stem cells for improvement of post-infarct myocardial regeneration in addition to bypass surgery: a controlled, prospective, randomized, double blinded, phase III, multicentric trial (PERFECT trial).
– G. Steinhoff (Rostock, DE) | 3 |
| 15:05 | Patients with refractory angina treated with peripheral blood-derived stem cells using the transendocardial injection route.
– P. Jimenez-Quevedo (Madrid, ES) | 4 |
| 15:20 | Comparison of intracoronary selected CD133⁺ bone marrow stem cells to placebo in cardiac recovery after acute myocardial infarction and left ventricular dysfunction (COMPARE - AMI trial).
– S. Mansour (Montreal, CA) | 5 |
| 15:35 | Intramyocardial application of stem cells in combination with transmyocardial laser revascularisation (TMLR) in bypass surgery patients (INSTEM trial).
– H.M. Klein (Dusseldorf, DE) | 6 |
| 15:50 | Discussion and conclusion: cellular therapy - Future aspects.
– F. Fernandez-Aviles (Madrid, ES) | 7 |

16:30 Opening Ceremony

No session

13:30 Coffee break

**FOR THE AT-RISK ACUTE CORONARY SYNDROME (ACS)
PATIENT: THE ERA OF TRIPLE ANTIPLATELET THERAPY**

Chairperson(s): M. Gibson (Boston, US); C.W. Hamm (Bad Nauheim, DE)
Satellite Symposium organised by theheart.org and Iroko Pharmaceuticals

Satellite

14:30	Introductions and introductory remarks. – M. Gibson (Boston, US)	8
14:40	Antiplatelet therapy in ACS: unmet needs. – C.W. Hamm (Bad Nauheim, DE)	9
14:55	Current guidelines for antiplatelet therapy in ACS. – J.-P. Bassand (Besançon, FR)	10
15:15	Triple antiplatelet therapy in STEMI. – A.W.J. Van 't Hof (Zwolle, NL)	11
15:35	Triple antiplatelet therapy in NSTEMI. – N. Uren (Edinburgh, GB)	12
15:55	Concluding remarks. – M. Gibson (Boston, US)	13

16:30 Opening Ceremony

No session

13:30 Coffee break

**INNOVATIVE HEART FAILURE MANAGEMENT: FROM
DIAGNOSIS TO THERAPY**

Satellite

Chairperson(s): J. Brugada Terradellas (Barcelona, ES); U. Sechtem (Stuttgart, DE)
Satellite Symposium organised by Siemens AG, Healthcare Sector and Medtronic

- | | | |
|-------|--|----|
| 14:30 | Introduction.
– U. Sechtem (Stuttgart, DE) | 14 |
| 14:35 | Clinical evidence for cardiac resynchronisation therapy.
– J.G.F. Cleland (Kingston upon Hull, GB) | 15 |
| 14:55 | Patient selection for cardiac resynchronisation therapy.
– J. Brachmann (Coburg, DE) | 16 |
| 15:15 | Magnetic resonance imaging safe devices: needs and clinical evidence.
– M.G. Bongiorno (Pisa, IT) | 17 |
| 15:35 | Biomarker enhanced heart failure therapy.
– A. Bayes Genis (Barcelona, ES) | 18 |
| 15:55 | Conclusions.
– J. Brugada Terradellas (Barcelona, ES) | 19 |

16:30 Opening Ceremony

No session

13:30 Coffee break

**EMERGING EVIDENCE IN THE MANAGEMENT OF
POST-MYOCARDIAL INFARCTION PATIENTS WITH HEART
FAILURE: UNDERSTANDING THE EFFECTS OF ALDOSTERONE
BLOCKADE**

Satellite

Chairperson(s): J.L. Lopez-Sendon (Madrid, ES); F. Zannad (Nancy, FR)
Satellite Symposium organised by Pfizer Inc.

14:30	Chairman's introduction. – J.L. Lopez-Sendon (Madrid, ES)	20
14:40	The effects of eplerenone on collagen biomarkers, neurohormones, and cytokines. – J.M. Ketelslegers (Brussels, BE)	21
15:00	Stratifying risk in patients with acute myocardial infarction. – M. Boehm (Homburg/Saar, DE)	22
15:20	Aldosterone blockade in the early phase of post-myocardial infarction treatment. – F. Zannad (Nancy, FR)	23
15:40	Question and answer session. – J.L. Lopez-Sendon (Madrid, ES)	24
15:50	Chairman's wrap-up and conclusions. – F. Zannad (Nancy, FR)	25

16:30 Opening Ceremony

HEART FAILURE MANAGEMENT – THE OUTLOOK IN 2009

EBAC Accredited Educational Programme organised by the Sahlgrenska Academy - Gothenburg University
Course Director: K. Swedberg (Gothenburg, SE)

Chairperson(s): M. Pfeffer (Boston, US); K. Swedberg (Gothenburg, SE)

12:00	Introductory remarks.	26
	– K. Swedberg (Gothenburg, SE)	
12:05	Role of blood pressure in the development and management of heart failure.	27
	– M. Pfeffer (Boston, US)	
12:25	Management of heart failure with preserved ejection fraction - What is the conclusion?	28
	– J.J.V. McMurray (Glasgow, GB)	
12:45	Heart failure guidelines in the light of new major trials.	29
	– K. Swedberg (Gothenburg, SE)	
13:05	Tailoring treatment of chronic heart failure to individual patients - Present and future.	30
	– C.B. Granger (Durham, US)	
13:25	Concluding remarks.	31
	– M. Pfeffer (Boston, US)	



"This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)."

Programme supported by an unrestricted educational grant from AstraZeneca

13:30 Coffee break

**ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE:
EVOLVING STRATEGIES TO IMPROVE PATIENT HEALTHCARE**

EBAC Accredited Educational Programme organised by the Sahlgrenska Academy - Gothenburg University
Course Director: K. Swedberg (Gothenburg, SE)

Chairperson(s): T.R. Pedersen (Oslo, NO); C.J. Packard (Glasgow, GB)

14:30	Towards comprehensive management of cardiovascular risk.	32
	– T.R. Pedersen (Oslo, NO)	
14:40	Residual risk of cardiovascular disease: identifying the at-risk patient.	33
	– G. De Backer (Ghent, BE)	
15:05	The atherosclerotic lesion - The role of inflammation and value of biomarkers.	34
	– J. Chapman (Paris, FR)	
15:30	Broadening our approach: looking beyond conventional risk assessment.	35
	– J.J.P. Kastelein (Amsterdam, NL)	
15:55	Future hopes and expectations.	36
	– C.J. Packard (Glasgow, GB)	



"This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)."

Programme supported by an unrestricted educational grant from AstraZeneca

16:30 Opening Ceremony

No session

13:30 Coffee break

MAKING THE RIGHT CHOICE FOR CARDIOVASCULAR PROTECTION

Satellite

Chairperson(s): M.E. Bertrand (Lambersart, FR); R. Ferrari (Ferrara, IT)
Satellite Symposium organised by Servier

14:00	Introduction. – M.E. Bertrand (Lambersart, FR)	37
14:05	Pivotal role of perindopril in cardiovascular disease. – M.L. Simoons (Rotterdam, NL)	38
14:25	Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: key role for coronary artery disease patients protection. – J.-C. Tardif (Montreal, CA)	39
14:45	Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors. – B.J. Levy (Paris, FR)	40
15:05	Perindopril/amlodipine combination: an optimal synergy for cardiovascular protection. – M.E. Bertrand (Lambersart, FR)	41
15:25	Conclusion. – R. Ferrari (Ferrara, IT)	42

16:30 Opening Ceremony

ANTICOAGULANT THERAPY IN ACUTE CORONARY SYNDROME (ACS): CONFRONTING PRACTICAL REALITIES **Satellite**

Chairperson(s): J.L. Lopez-Sendon (Madrid, ES); F.W.A. Verheugt (Amsterdam, NL)
Satellite Symposium organised by sanofi-aventis

12:00	Welcome and introduction. – J.L. Lopez-Sendon (Madrid, ES)	43
12:05	Anticoagulant therapy in non-ST-elevation (NSTEMI) ACS: the ESC perspective. – K.A.A. Fox (Edinburgh, GB)	44
12:20	Stress testing the ESC NSTEMI ACS guidelines. – G. Montalescot (Paris, FR)	45
12:45	Anticoagulant therapy in STEMI: the ESC perspective. – F.W.A. Verheugt (Amsterdam, NL)	46
13:00	Stress testing the ESC STEMI guidelines. – M. Cohen (Newark, US)	47
13:20	Closing remarks. – F.W.A. Verheugt (Amsterdam, NL)	48

13:30 Coffee break

NEW PERSPECTIVES IN LONG-TERM ANTICOAGULATION: AN INNOVATIVE APPROACH TO IMPROVE PATIENT MANAGEMENT **Satellite**

Chairperson(s): J. Halperin (New York, US); G. Montalescot (Paris, FR)
Satellite Symposium organised by sanofi-aventis

14:00	Welcome and introduction. – G. Montalescot (Paris, FR)	49
14:05	The burden of thromboembolic disease: a challenge for clinicians and healthcare systems. – P.G. Steg (Paris, FR)	50
14:25	Is there room for improvement in long-term anticoagulation therapy? The patient's perspective. – M. Cohen (Newark, US)	51
14:45	Meeting patients' needs with a once-weekly reversible anticoagulant: what is on the horizon? – A. Cohen (London, GB)	52
15:15	Panel discussion and close. – A. Cohen, M. Cohen, J. Halperin, G. Montalescot, P.G. Steg (London, GB; Newark and New York, US; Paris, FR)	53

16:30 Opening Ceremony

No session

13:30 Coffee break

WHAT MORE CAN WE ACHIEVE BEYOND MONO AND COMBINATION THERAPY FOR HYPERTENSION MANAGEMENT?

Satellite

Chairperson(s): H. Haller (Hannover, DE); H.L. Elliott (Glasgow, GB)
Satellite Symposium organised by Bayer Schering Pharma AG

- | | | |
|-------|---|----|
| 14:30 | Introduction.
– H. Haller (Hannover, DE) | 54 |
| 14:35 | Extending the blood pressure - lowering benefits of nifedipine gastrointestinal therapeutic system (GITS) to patients with isolated systolic hypertension (ISH).
– H.L. Elliott (Glasgow, GB) | 55 |
| 14:55 | Blood pressure reduction and clinical outcomes - Update from ONTARGET.
– R. Asmar (Paris, FR) | 56 |
| 15:15 | Challenges in treating metabolic syndrome - The advantages of prescribing angiotensin receptor blockers alone and in combination.
– A. De La Sierra (Barcelona, ES) | 57 |
| 15:35 | Combining antihypertensive drug classes - Extending the evidence and maximising the benefits.
– P. Meredith (Glasgow, GB) | 58 |
| 15:55 | Summary and closing remarks.
– H.L. Elliott (Glasgow, GB) | 59 |

16:30 Opening Ceremony

CARDIAC COMPUTED TOMOGRAPHY, REFINEMENT IN DIAGNOSTICS AND BEYOND

Satellite

Chairperson(s): F. Carreras Costa (Barcelona, ES); R.G. Leta Petracca (Barcelona, ES)
Satellite Symposium organised by Toshiba Medical Systems

12:00	Introduction. – F. Carreras Costa, R.G. Leta Petracca (Barcelona, ES)	60
12:05	Plaque detection and qualification with Toshiba CT in clinical practice. – G. Pundziute (Leiden, NL)	61
12:30	SURECardio prospective and innovative dose saving application in coronary artery disease detection. – K.F. Kofoed (Copenhagen, DK)	62
12:55	320 detector row CT applications: the role of myocardial perfusion imaging. – R. George (Baltimore, US)	63
13:20	Conclusion. – F. Carreras Costa, R.G. Leta Petracca (Barcelona, ES)	64

13:30 Coffee break

2D AND 3D WALL MOTION TRACKING (WMT): EXPERIENCES ON LEFT VENTRICAL (LV) FUNCTION

Satellite

Chairperson(s): H.-J. Nesser (Linz, AT); J. Gorcsan (Pittsburgh, US)
Satellite Symposium organised by Toshiba Medical Systems

14:00	Introduction. – H.-J. Nesser, J. Gorcsan (Linz, AT; Pittsburgh, US)	65
14:03	3D WMT new parameters for LV function. – A. Evangelista (Rome, IT)	66
14:26	Clinical value and experience with 3D WMT. – L. Peres de Isla (Madrid, ES)	67
14:49	2D and 3D WMT in cardiac resynchronization. – J. Gorcsan (Pittsburgh, US)	68
15:11	Case studies: use of new technologies in clinical practice. – M. Zuber (Othmarsingen, CH)	69
15:25	Conclusion. – H.-J. Nesser, J. Gorcsan (Linz, AT; Pittsburgh, US)	70

16:30 Opening Ceremony

No session

13:30 Coffee break

GETTING HIGH RISK PATIENTS TO AGGRESSIVE LOW-DENSITY LIPOPROTEIN-C GOALS WITH COMBINATION THERAPY **Satellite**

Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); D. Atar (Oslo, NO)
Satellite Symposium organised by MSD/Schering-Plough Pharmaceuticals

- | | | |
|-------|--|-----------|
| 14:30 | Welcome and opening remarks. | 71 |
| | – J.L. Zamorano Gomez (Madrid, ES) | |
| 14:35 | Reaching LDL-C goals: understanding current gaps in treatment. | 72 |
| | – A.K. Gitt (Ludwigshafen, DE) | |
| 15:00 | Unique mechanism of action: the difference in reaching more aggressive LDL-C targets. | 73 |
| | – M. Farnier (Dijon, FR) | |
| 15:25 | Managing high risk patients with CHD: a cost effectiveness approach. | 74 |
| | – A. Catapano (Milan, IT) | |
| 15:45 | Closing remarks and panel discussion. | 75 |
| | – D. Atar (Oslo, NO) | |

16:30 Opening Ceremony

RECENT THERAPEUTIC DEVELOPMENTS IN THE FIELD OF PULMONARY ARTERIAL HYPERTENSION **Satellite**

Chairperson(s): M.A. Gomez Sanchez (Pozuelo De Alarcon, ES); N. Galie (Bologna, IT)
Satellite Symposium organised by Eli Lilly and Company

12:00	Introductions. – M.A. Gomez Sanchez, N. Galie (Pozuelo De Alarcon, ES; Bologna, IT)	76
12:05	What is new in the diagnosis of pulmonary arterial hypertension? – S. Gibbs (London, GB)	77
12:20	What is new in risk stratification? – A. Torbicki (Warsaw, PL)	78
12:35	New classes of drugs in development. – G. Simonneau (Clamart, FR)	79
12:50	Tadalafil, a new molecule in the clinical arena. – N. Galie (Bologna, IT)	80
13:05	Discussion and Q & A session. – N. Galie, S. Gibbs, M.A. Gomez Sanchez, G. Simonneau, A. Torbicki (Bologna, IT; London, GB; Pozuelo De Alarcon, ES; Clamart, FR; Warsaw, PL)	81
13:25	Closing remarks.	82

13:30 Coffee break

No session

16:30 Opening Ceremony

No session

13:30 Coffee break

FROM CHALLENGES TO SOLUTIONS IN HYPERTENSION

Satellite

Chairperson(s): S. Laurent (Paris, FR); J. Redon (Valencia, ES)

Satellite Symposium organised by Daiichi Sankyo Europe GmbH and Menarini International

14:30	Introduction. – S. Laurent (Paris, FR)	83
14:35	Hypertension: a call for action! – J. Redon (Valencia, ES)	84
14:55	Combining and what to combine, that's the question! – R. Kreutz (Berlin, DE)	85
15:15	Protection around the clock: olmesartan/amlodipine study results. – G. Parati (Monza, IT)	86
15:35	The future and beyond. – R. Schmieder (Erlangen, DE)	87
15:55	Conclusion. – J. Redon (Valencia, ES)	88

16:30 Opening Ceremony

No session

13:30 Coffee break

LATEST ADVANCES IN 2D AND LIVE 3D ECHOCARDIOGRAPHY **Satellite**

Chairperson(s): R.M. Lang (Chicago, US); Z. Bulbul (Riyadh, SA)
Satellite Symposium organised by Philips Healthcare

14:30	Introduction. – R.M. Lang, Z. Bulbul (Chicago, US; Riyadh, SA)	89
14:35	Mobile echo service is improving the echo workflow. – F.V. Steensgaard-Hansen (Copenhagen, DK)	90
14:55	Live 3D transoesophageal echocardiography (TEE) is 2 years old: how is its use evolving in clinical practice? – R.M. Lang (Chicago, US)	91
15:15	Live 3D has modified clinical decision making in the echolab. – T. Buck (Essen, DE)	92
15:35	Live 3D echo: customise and improve surgery for mitral valve repair. – P. Punjabi (London, GB)	93
15:55	Conclusion. – R.M. Lang, Z. Bulbul (Chicago, US; Riyadh, SA)	94

16:30 Opening Ceremony

No session

13:30 Coffee break

EVOLVING TREATMENT GOALS IN HYPERTENSION AND HEART FAILURE: ROLE OF THE ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) **Satellite**

Chairperson(s): M.R. Cowie (London, GB); L.M. Ruilope (Madrid, ES)
Satellite Symposium organised by Takeda Pharmaceuticals Europe Limited

14:30	Welcome and introductions. – M.R. Cowie (London, GB)	95
14:35	Organ protection with ARBs: evolving benefits in the hypertensive patient. – P. Meredith (Glasgow, GB)	96
14:55	Optimising hypertension management: are we doing enough? – G. Bonner (Bad-Krozingen, DE)	97
15:20	Protective effects of ARBs in heart failure: are all ARBs the same? – L.M. Ruilope (Madrid, ES)	98
15:45	Panel discussion. – M.R. Cowie (London, GB)	99
15:55	Conclusions and meeting end. – M.R. Cowie (London, GB)	100

16:30 Opening Ceremony

**EMERGING THERAPEUTIC STRATEGIES FOR THE TREATMENT
OF OSTEOARTHRITIS (OA) PATIENTS WITH HYPERTENSION:
THE PHYSIOLOGIC AND PHARMACOLOGIC EFFECTS OF
NITRIC OXIDE**

EBAC Accredited Educational Programme organised by the University Hospital Zurich
Course Director: T. Luscher (Zurich, CH)

Chairperson(s): T. Luscher (Zurich, CH); P. Verdecchia (Perugia, IT)

12:00	Welcome & introduction. – T. Luscher (Zurich, CH)	101
12:10	Current issues in the therapeutic management of OA. – T.M. MacDonald (Dundee, GB)	102
12:30	Physiologic & pharmacologic effects of nitric oxide. – U. Forstermann (Mainz, DE)	103
12:50	Emerging therapeutic strategies in the management of OA patients with hypertension. – P. Verdecchia (Perugia, IT)	104
13:10	Panel discussion.	105



"This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS)."

Programme supported by an unrestricted educational grant from NicOx SA

13:30 Coffee break

No session

16:30 Opening Ceremony